非戈替尼治疗类风湿关节炎患者的疗效与安全性:长期扩展研究第156周中期结果
FINCH 4长期扩展研究第156周中期结果显示,非戈替尼200 mg和100 mg(持续或新起始)在FINCH 1、2或3入组患者中维持疗效,安全性与已知特征一致,无意外安全性结果。
要点
- 甲氨蝶呤应答不足患者中,新起始非戈替尼200 mg和100 mg第156周ACR20分别为60.2%和54.6%。
- 持续非戈替尼200 mg和100 mg患者第156周ACR20分别为67.3%和59.5%。
- 第156周Boolean缓解1.0在新起始200 mg和100 mg分别为18.8%和15.4%,Boolean 2.0分别为21.1%和18.5%。
核心结论
- 在FINCH 4中,非戈替尼200 mg和100 mg(持续或新起始)在FINCH 1、2或3入组患者中显示持续至第156周的疗效,无意外安全性结果。
研究设计与样本
- 正在进行的长期扩展研究FINCH 4(NCT03025308),患者从FINCH 1、2或3继续非戈替尼200 mg或100 mg,或新起始非戈替尼200 mg或100 mg。
主要发现
- 甲氨蝶呤应答不足患者中,新起始非戈替尼200 mg和100 mg第156周ACR20分别为60.2%和54.6%,持续200 mg和100 mg分别为67.3%和59.5%。
- 第156周Boolean缓解1.0在新起始非戈替尼200 mg和100 mg分别为18.8%和15.4%,Boolean 2.0分别为21.1%和18.5%。
- 来自FINCH 2和3的患者中观察到相似疗效数据。
- 安全性数据与已知非戈替尼安全性特征一致。
关键数值与推荐
- 疗效评估包括ACR20、DAS28-CRP<2.6、CDAI≤2.8、SDAI≤3.3和Boolean缓解(1.0和2.0),采用无应答填补。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Janus kinase inhibitors are an effective option for achieving sustained remission or low disease activity in patients with rheumatoid arthritis (RA) following inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs. Filgotinib is a Janus kinase 1-preferential inhibitor available in two doses for moderate-to-severe RA. We report the long-term efficacy and safety of filgotinib. METHODS: In the ongoing long-term extension study FINCH 4 (NCT03025308), patients continue filgotinib 200 mg or 100 mg from FINCH 1, 2 or 3 or receive filgotinib 200 mg or 100 mg de novo. Efficacy assessments up to week 156 include American College of Rheumatology 20% response (ACR20), Disease Activity Score 28 using C-reactive protein of <2.6, Clinical Disease Activity Index of ≤2.8, Simplified Disease Activity Index of ≤3.3 and Boolean remission (1.0 and 2.0) with non-responder imputation. RESULTS: In patients with an inadequate response to methotrexate, 60.2% and 54.6% receiving de novo filgotinib 200 mg and 100 mg had an ACR20 at week 156, respectively, as did 67.3% and 59.5% of those who continued filgotinib 200 mg and 100 mg. At week 156, Boolean remission 1.0 was achieved by 18.8% and 15.4% of patients treated with de novo filgotinib 200 mg and 100 mg, respectively, and by 21.1% and 18.5% when Boolean 2.0 criteria were applied. Similar efficacy data were seen in patients from FINCH 2 and 3. Safety data were consistent with the known safety profile of filgotinib. CONCLUSION: In FINCH 4, filgotinib 200 mg and 100 mg (continuous or de novo) demonstrated sustained efficacy up to week 156 in patients enrolled from FINCH 1, 2 or 3, with no unexpected safety results.
引用
- Buch MH, Aletaha D, Combe BG, et al. Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study. RMD Open. 2024. PMID: 39455065. doi:10.1136/rmdopen-2024-004476
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。